Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins

► Intracellular antibody fragments (intrabodies) can be selected against toxic proteins. ► Intrabodies offer a targeted proteomic approach to polyglutamine toxicity. ► Phenotypic correction has been shown in Huntington's cell and animal models. ► Antibody engineering allows bifunctionality, and enhanced stability and efficacy. ► HD intrabody studies validate this technology for other neurodegenerative diseases.